Efficacy of first-line CDK 4-6 inhibitors in premenopausal patients with metastatic breast cancer and the effect of dose reduction due to treatment-related neutropenia on efficacy: a Turkish Oncology Group (TOG) study.

Autor: Yildirim HC; Department of Medical Oncology, Hacettepe University Cancer Institute, Ankara, Turkey.; Department of Medical Oncology, Nigde Research and Education Hospital, Nigde, Turkey., Kapar C; Department of Medical Oncology, Bakırkoy Dr. Sadi Konuk Education and Research Hospital, İstanbul, Turkey., Koksal B; Department of Medical Oncology, Hacettepe University Cancer Institute, Ankara, Turkey., Seyyar M; Department of Medical Oncology, Kocaeli University Faculty of Medicine, Kocaeli, Turkey., Sanci PC; Department of Medical Oncology, Kocaeli University Faculty of Medicine, Kocaeli, Turkey., Guliyev M; Department of Medical Oncology, Istanbul Cerrahpasa University Faculty of Medicine, Istanbul, Turkey., Perkin P; Department of Medical Oncology, Yildirim Beyazit University, Bilkent State Hospital, Ankara, Turkey., Buyukkor M; Department of Medical Oncology, Dr. A. Y. Ankara Oncology Research and Education Hospital, University of Health Sciences, Ankara, Turkey., Yaslikaya S; Department of Medical Oncology, Cukurova University Faculty of Medicine, Adana, Turkey., Majidova N; Department of Medical Oncology, Marmara University Faculty of Medicine, Istanbul, Turkey., Keskinkilic M; Department of Medical Oncology, 9 Eylül University Faculty of Medicine, Izmir, Turkey., Ozaskin D; Department of Medical Oncology, Afyon Health Sciences University School of Medicine, Afyonkarahisar, Turkey., Avci T; Department of Medical Oncology, Celal Bayar University Faculty of Medicine, Manisa, Turkey., Gunes TK; Department of Medical Oncology, Umraniye Research and Education Hospital, Istanbul, Turkey., Arcagok M; Department of Medical Oncology, Dicle University Faculty of Medicine, Diyarbakir, Turkey., Topal A; Department of Medical Oncology, University of Health Sciences, Gulhane School of Medicine, Ankara, Turkey., Keskin GSY; Department of Medical Oncology, University of Health Sciences, Gulhane School of Medicine, Ankara, Turkey., Kavgaci G; Department of Medical Oncology, Hacettepe University Cancer Institute, Ankara, Turkey., Yildirim N; Department of Medical Oncology, Firat University Faculty of Medicine, Elazig, Turkey., Celayir OM; Department of Medical Oncology, Acibadem University Faculty of Medicine, Istanbul, Turkey., Avci N; Department of Medical Oncology, Medicana Hospital, Bursa, Turkey., Aslan F; Department of Medical Oncology, Medical Park Ankara Hospital, Ankara, Turkey., Alkan A; Department of Medical Oncology, Mugla Sitki Kocman University Faculty of Medicine, Mugla, Turkey., Erciyestepe M; Department of Medical Oncology, Istanbul Prof. Dr. Cemil Tascioglu State Hospital, Istanbul, Turkey., Cengiz M; Department of Medical Oncology, Erciyes University Faculty of Medicine, Kayseri, Turkey., Pehlivan M; Department of Medical Oncology, Zonguldak Ataturk State Hospital, Zonguldak, Turkey., Gulmez A; Department of Medical Oncology, Adana City Education and Research Hospital, Adana, Turkey., Beypinar I; Department of Medical Oncology, Alaaddin Keykubat University Faculty of Medicine, Antalya, Turkey., Basoglu Tuylu T; Department of Medical Oncology, Nigde Research and Education Hospital, Nigde, Turkey., Kayikcioglu E; Department of Medical Oncology, Isparta Suleyman Demirel University Faculty of Medicine, Isparta, Turkey., Chalabiyev E; Department of Medical Oncology, Hacettepe University Cancer Institute, Ankara, Turkey., Turhal S; Department of Medical Oncology, Anadolu Health Center, Istanbul, Turkey., Guzel HG; Department of Medical Oncology, Antalya Education and Research Hospital, Antalya, Turkey., Ayas E; Department of Medical Oncology, Karadeniz Technical University Faculty of Medicine, Trabzon, Turkey., Sahbazlar M; Department of Medical Oncology, Celal Bayar University Faculty of Medicine, Manisa, Turkey., Dulgar O; Department of Medical Oncology, Umraniye Research and Education Hospital, Istanbul, Turkey., Demir H; Department of Medical Oncology, Afyon Health Sciences University School of Medicine, Afyonkarahisar, Turkey., Yavuzsen T; Department of Medical Oncology, 9 Eylül University Faculty of Medicine, Izmir, Turkey., Bayoglu V; Department of Medical Oncology, Marmara University Faculty of Medicine, Istanbul, Turkey., Kivrak Salim D; Department of Medical Oncology, Antalya Education and Research Hospital, Antalya, Turkey., Ozturk B; Department of Medical Oncology, Antalya Education and Research Hospital, Antalya, Turkey., Ozdemir F; Department of Medical Oncology, Karadeniz Technical University Faculty of Medicine, Trabzon, Turkey., Kara O; Department of Medical Oncology, Cukurova University Faculty of Medicine, Adana, Turkey., Oksuzoglu B; Department of Medical Oncology, Dr. A. Y. Ankara Oncology Research and Education Hospital, University of Health Sciences, Ankara, Turkey., Bal O; Department of Medical Oncology, Yildirim Beyazit University, Bilkent State Hospital, Ankara, Turkey., Demirci NS; Department of Medical Oncology, Istanbul Cerrahpasa University Faculty of Medicine, Istanbul, Turkey., Yilmaz M; Department of Medical Oncology, Bakırkoy Dr. Sadi Konuk Education and Research Hospital, İstanbul, Turkey., Cabuk D; Department of Medical Oncology, Kocaeli University Faculty of Medicine, Kocaeli, Turkey., Aksoy S; Department of Medical Oncology, Hacettepe University Cancer Institute, Ankara, Turkey.

Publikováno v: Journal of chemotherapy (Florence, Italy) [J Chemother] 2024 Mar 18, pp. 1-7. Date of Electronic Publication: 2024 Mar 18.

Prognostic value of preoperative neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in patients with epithelial ovarian cancer

Autor: Salman, T., Alacacioglu, A., Kucukzeybek, Y., Yildiz, Y., Tarhan, M. O., Oflazoglu, U., Bayoglu, V., Taskaynatan, H., Kabadayi, G., Akyol, M., Yildiz, I., Varol, U.

Purpose: The neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) have recently been evaluated in many cancers in prediction of survival outcomes. The purpose of this study was to investigate the impact of NLR and PLR on the pr

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______2605::0aaa659e54e6fa74b873f09d3bd2b3df
https://avesis.deu.edu.tr/publication/details/cad379b8-e3b8-407e-bfc6-57320792949a/oai

Total Neoadjuvant Therapy Versus Neoadjuvant Chemoradiation for Locally Advanced Rectal Cancer: A Multi-Institutional Real-World Study.

Autor: Şenocak Taşçı, Elif¹ (AUTHOR) esenocak@gmail.com, Mutlu, Arda Ulaş² (AUTHOR), Saylık, Onur³ (AUTHOR) onur.saylik@acibadem.com, Ölmez, Ömer Fatih⁴ (AUTHOR) abilici@medipol.edu.tr, Bilici, Ahmet⁴ (AUTHOR), Sünger, Erdem⁴ (AUTHOR), Sütçüoğlu, Osman⁵ (AUTHOR), Çakmak Öksüzoğlu, Ömür Berna⁵ (AUTHOR), Özdemir, Nuriye⁶ (AUTHOR) nuriyeozdemir@gazi.edu.tr, Akdoğan, Orhun⁶ (AUTHOR) orhunakdogan@gazi.edu.tr, Bayoğlu, İbrahim Vedat⁷ (AUTHOR), Majidova, Nargiz⁷ (AUTHOR), Güren, Ali Kaan⁷ (AUTHOR), Özen Engin, Esra⁸ (AUTHOR), Hacıbekiroğlu, İlhan⁸ (AUTHOR), Er, Özlem⁹ (AUTHOR) ozlem.er@acibadem.com, Dane, Faysal¹⁰ (AUTHOR) faysal.dane@acibadem.com, Bozkurt, Mustafa¹¹ (AUTHOR) mustafa.bozkurt@acibadem.com, Turan Canbaz, Esra¹² (AUTHOR), Erdamar, Sibel¹³ (AUTHOR) sibel.erdamar@acibadem.com

Publikováno v: Cancers. Sep2024, Vol. 16 Issue 18, p3213. 11p.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

The alterations of serum FGF-21 levels, metabolic and body composition in early breast cancer patients receiving adjuvant endocrine therapy.

Autor: Akyol M; Department of Medical Oncology, Manisa State Hospital, Manisa, Turkey., Alacacioglu A; Department of Medical Oncology, Izmir Katip Celebi University Ataturk Training and Research Hospital, Izmir, Turkey., Demir L; Department of Biochemistry, Izmir Katip Celebi University Ataturk Training and Research Hospital, Izmir, Turkey., Kucukzeybek Y; Department of Medical Oncology, Izmir Katip Celebi University Ataturk Training and Research Hospital, Izmir, Turkey., Yildiz Y; Department of Medical Oncology, Izmir Katip Celebi University Ataturk Training and Research Hospital, Izmir, Turkey., Gumus Z; Department of Medical Oncology, Izmir Katip Celebi University Ataturk Training and Research Hospital, Izmir, Turkey., Kara M; Department of Medical Oncology, Izmir Katip Celebi University Ataturk Training and Research Hospital, Izmir, Turkey., Salman T; Department of Medical Oncology, Izmir Katip Celebi University Ataturk Training and Research Hospital, Izmir, Turkey., Varol U; Department of Medical Oncology, Izmir Katip Celebi University Ataturk Training and Research Hospital, Izmir, Turkey., Taskaynatan H; Department of Medical Oncology, Izmir Katip Celebi University Ataturk Training and Research Hospital, Izmir, Turkey., Oflazoglu U; Department of Medical Oncology, Izmir Katip Celebi University Ataturk Training and Research Hospital, Izmir, Turkey., Bayoglu V; Department of Medical Oncology, Izmir Katip Celebi University Ataturk Training and Research Hospital, Izmir, Turkey., Tarhan MO; Institute of Oncology, Dokuz Eylul University, Izmir, Turkey.

Publikováno v: Cancer biomarkers : section A of Disease markers [Cancer Biomark] 2017; Vol. 18 (4), pp. 441-449.